OBJECTIVE: To evaluate visual field abnormalities after an episode of optic neuritis among participants in the Optic Neuritis Treatment Trial. METHODS:Three readers independently evaluated 10 443 visual fields from 454 patients and classified visual field abnormalities into 21 different monocular categories representing 3 general types of visual loss: diffuse, localized, and artifactual. Classification frequency was determined and reader agreement was evaluated. The association of visual field abnormality classifications with mean deviation, pattern standard deviation, visual acuity, and foveal threshold was assessed. RESULTS: At baseline, diffuse loss accounted for 66.2% of the abnormalities in the affected eyes but only 6.2% of the abnormalities in the fellow eyes. During years 1 through 15, the affected and fellow eyes exhibited predominantly localized loss in the nerve fiber bundle region (partial arcuate, paracentral, and arcuate defects). At year 1, 35.7% of the abnormalities in the affected eyes and 34.4% in the fellow eyes consisted of localized defects. At year 15, 39.5% of abnormalities in the affected eyes and 26.3% in the fellow eyes consisted of localized defects. Foveal threshold was highly correlated with visual acuity and contrast sensitivity in the affected eye at baseline (-0.82 vs 0.79, respectively), 6 months (-0.84 vs 0.81), and 1 year (-0.84 vs 0.79). CONCLUSIONS:Diffuse and central loss were more predominant in the affected eye at baseline, and nerve fiber bundle defects (partial arcuate, paracentral, and arcuate) were the most predominant localized abnormalities in both the affected and fellow eyes during the study.
RCT Entities:
OBJECTIVE: To evaluate visual field abnormalities after an episode of optic neuritis among participants in the Optic Neuritis Treatment Trial. METHODS: Three readers independently evaluated 10 443 visual fields from 454 patients and classified visual field abnormalities into 21 different monocular categories representing 3 general types of visual loss: diffuse, localized, and artifactual. Classification frequency was determined and reader agreement was evaluated. The association of visual field abnormality classifications with mean deviation, pattern standard deviation, visual acuity, and foveal threshold was assessed. RESULTS: At baseline, diffuse loss accounted for 66.2% of the abnormalities in the affected eyes but only 6.2% of the abnormalities in the fellow eyes. During years 1 through 15, the affected and fellow eyes exhibited predominantly localized loss in the nerve fiber bundle region (partial arcuate, paracentral, and arcuate defects). At year 1, 35.7% of the abnormalities in the affected eyes and 34.4% in the fellow eyes consisted of localized defects. At year 15, 39.5% of abnormalities in the affected eyes and 26.3% in the fellow eyes consisted of localized defects. Foveal threshold was highly correlated with visual acuity and contrast sensitivity in the affected eye at baseline (-0.82 vs 0.79, respectively), 6 months (-0.84 vs 0.81), and 1 year (-0.84 vs 0.79). CONCLUSIONS: Diffuse and central loss were more predominant in the affected eye at baseline, and nerve fiber bundle defects (partial arcuate, paracentral, and arcuate) were the most predominant localized abnormalities in both the affected and fellow eyes during the study.
Authors: Chris A Johnson; John L Keltner; Kimberly E Cello; Mary Edwards; Michael A Kass; Mae O Gordon; Donald L Budenz; Douglas E Gaasterland; Elliot Werner Journal: Ophthalmology Date: 2002-03 Impact factor: 12.079
Authors: John L Keltner; Chris A Johnson; Kimberly E Cello; Mary A Edwards; Shannan E Bandermann; Michael A Kass; Mae O Gordon Journal: Arch Ophthalmol Date: 2003-05
Authors: Deanna Cettomai; Mathew Pulicken; Eliza Gordon-Lipkin; Amber Salter; Teresa C Frohman; Amy Conger; Xiao Zhang; Gary Cutter; Laura J Balcer; Elliot M Frohman; Peter A Calabresi Journal: Arch Neurol Date: 2008-09
Authors: Zane S Schnurman; Teresa C Frohman; Shin C Beh; Darrel Conger; Amy Conger; Shiv Saidha; Steven Galetta; Peter A Calabresi; Ari J Green; Laura J Balcer; Elliot M Frohman Journal: Neurology Date: 2014-04-30 Impact factor: 9.910
Authors: John L Keltner; Kimberly E Cello; Laura J Balcer; Peter A Calabresi; Clyde E Markowitz; John S Werner Journal: Neuroophthalmology Date: 2011-03-20
Authors: Santiago Ortiz-Perez; Magí Andorra; Bernardo Sanchez-Dalmau; Rubén Torres-Torres; David Calbet; Erika J Lampert; Salut Alba-Arbalat; Ana M Guerrero-Zamora; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; María Sepúlveda; Albert Saiz; Pablo Villoslada; Elena H Martinez-Lapiscina Journal: J Neurol Date: 2016-02-09 Impact factor: 4.849
Authors: Reiko E Sakai; Daniel J Feller; Kristin M Galetta; Steven L Galetta; Laura J Balcer Journal: J Neuroophthalmol Date: 2011-12 Impact factor: 3.042
Authors: Axel Petzold; Mike P Wattjes; Fiona Costello; Jose Flores-Rivera; Clare L Fraser; Kazuo Fujihara; Jacqueline Leavitt; Romain Marignier; Friedemann Paul; Sven Schippling; Christian Sindic; Pablo Villoslada; Brian Weinshenker; Gordon T Plant Journal: Nat Rev Neurol Date: 2014-07-08 Impact factor: 42.937